Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading stock research

Loading market dashboard

My Watchlist

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading stock research

Sionna Therapeutics, Inc.

SION

HealthcareNASDAQUS

$35.37

-$2.41 (-6.38%)

Overview Financials Analysis Valuation Thesis Ownership Compare AI Report News

SION

1Y-2.41 (-6.38%)

Candles, volume, SMA 20, and SMA 50

O 37.55H 37.95L 35.25C 35.37Date Jun 5

SION

SMA 20 SMA 50 Vol 461.30KEEarnings dates

Open in Chartsfor further analysis

Business Description

Open for the full company profile when you need deeper context.

ShowHide

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Key Metrics

Quick size, liquidity, and volatility measures for the stock.

Market Cap?$1.60B

Volume?461.28K

Avg Volume?391.80K

52w Range$13.51 - $48.445

Beta?1.29

Price Performance

-18.3%

$43.31 to $35.37

YTD

-14.0%

$41.14 to $35.37

+105.4%

$17.22 to $35.37

N/A

history unavailable

N/A

history unavailable

10Y

N/A

history unavailable

Company Details

CEO, industry, employees, IPO date, currency, and website.

ShowHide

CEOMichael Cloonan

IndustryBiotechnology

Employees41

IPO Date2025-02-07

CurrencyUSD

Websitewww.sionnatx.com

Related stocks

Check out other names from the same Biotechnology industry as SION.

ABCL-

AbCellera Biologics Inc.

Celldex Therapeutics, Inc.

Janux Therapeutics, Inc.

13.36USD

-2.91%

MAZE-

Maze Therapeutics, Inc.

24.27USD

-4.45%

VERA-

Vera Therapeutics, Inc.

32.29USD

-3.27%

XERS-

Xeris Biopharma Holdings, Inc.